US pandemic preparedness got a boost with the Center for Biologics Evaluation and Research’s approval of Seqirus’ Audenz, a pandemic influenza A (H5N1) vaccine destined for the national stockpile, while Trevena Inc. tried to chip away at another issue of national significance – the opioid crisis – with the resubmission of its novel IV opioid for acute pain, oliceridine.
Competition for Genentech Inc.’s Lucentis was delayed by the withdrawal of the first application for a biosimilar, thanks to...